FDA
No application listedNo application naming AOD-9604 or AOD9604 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDAAOD-9604: chemistry, literature and regulatory status
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is AOD-9604?
AOD-9604 is a synthetic peptide made of the C-terminal fragment of human growth hormone, amino acids 177 to 191, with an added N-terminal tyrosine and a disulfide bridge. Published work is limited to rodent studies and analytical detection. It is supplied here as a research material for laboratory use only.
What are the chemical facts for AOD-9604?
- Name
- AOD-9604
- Also written
- hGH fragment 176-191
- Sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- Length
- 16 residues
- Molecular formula
C78H123N23O23S2(matches the formula computed from the sequence)- Average molecular weight
- 1815.1 g/mol
- CAS number
221231-10-3(confirmed in PubChem)- PubChem
- CID 71300630
Chemistry checked against PubChem on 2026-10-05. Where the formula can be computed from the listed sequence, it was, and the two routes agree.
How does the literature describe the mechanism of AOD-9604?
What has published research on AOD-9604 looked at?
3 studies are cited for AOD-9604. Each is labelled by design below, and each entry says what the paper measured.
- 2 animal study
- 1 analytical chemistry
PubMed returns 23 records for the search terms published on the method page (9 of them with a review publication type, 0 with a clinical-trial publication type), checked 5 October 2026. ClinicalTrials.gov lists 0 registered studies whose intervention matches the name (0 interventional), checked 5 October 2026.
- An analytical paper describes detection and in vitro metabolism of AOD9604 for anti-doping analysis.[1]
Studies are listed by what they measured. Papers whose titles state an amount or schedule, or describe a clinical outcome of an approved medicine, are not listed. This is a wording rule, not a quality filter; see the method page.
What is the regulatory status of AOD-9604?
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names AOD9604 as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "AOD-9604". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S2.2.3The WADA 2026 Prohibited List, in force 1 January 2026 names AOD-9604 under S2.2.3 (growth hormone (gh), its analogues and fragments). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05.
Which studies are cited for AOD-9604?
[1] Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7:31-8.
Detection and in vitro metabolism of AOD9604 for anti-doping analysis; notes its WADA prohibition.
[2] Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, et al.. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142:5182-9.
Studied the beta-adrenergic pathway and lipid metabolism in rodents treated with human growth hormone or AOD9604.
[3] Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53:274-8.
Studied metabolic actions of AOD9604 in obese Zucker rats, including adipose tissue changes.
Data dates: citations read from PubMed 2026-10-05.
Where else in the research library is AOD-9604 covered?
Who wrote this page and how is it checked?
Peptency editorial team, last reviewed 5 October 2026. Citations are read back from PubMed, chemistry is checked against PubChem, and regulator records are read from each regulator's own database on the dates shown. The method page lists every source, search term and rule. Corrections are welcome through the contact details on the About page.